The effect of imaging time, radiopharmaceutical, full fat milk and water on interfering extra-cardiac activity in myocardial perfusion single photon emission computed tomography

Nuclear Medicine Communications

Volumn 26, Issue 1, 2005, Pages 17-24

  Peace, Richard A ^a   Lloyd, Jim J ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Extra cardiac activity; Image quality; Myocardial perfusion; SPECT

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MILK FAT; RADIOPHARMACEUTICAL AGENT; TETROFOSMIN TC 99M; WATER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE PERFUSION; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MILK; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WATER;

EID: 13244283079     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200501000-00004     Document Type: Article

References (34)

1. Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl)phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34:30-34.
2. Wackers FJ, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989; 30:301-311.
3. Heller EN, DeMan P, Liu Y-H, Dione DP, Zubal Z, Wackers FJT, et al. Extracardiac activity complicates quantitative cardiac SPECT imaging using a simultaneous transmission-emission approach. J Nucl Med 1997; 38:1882-1890.
4. Germano G, Chua T, Kiat H, Areeda JS, Berman DS. A quantitative phantom analysis of artefacts due to hepatic activity in technetium-99m myocardial perfusion SPECT studies. J Nucl Med 1994; 35:356-359.
5. Garcia E, Cooke CD, Van Train KF, Folks R, Peifer J, DePuey EG. Technical aspects of myocardial SPECT imaging with technetium-99m sestamibi. Am J Cardiol 1990; 66(suppl):80E-90E.
6. van Dongen AJ, van Rijk PP. Minimizing liver, bowel, and gastric activity in myocardial perfusion SPECT. J Nucl Med 2000; 41:1315-1317.
7. Hurwitz GA, Clark EM, Slomka PJ, Siddiq SK. Investigations of measures to reduce interfering abdominal activity on rest myocardial images with Tc-99m-sestamibi. Clin Nucl Med 18:735-741.
8. m-MIBI cardiac SPET interpretation. Nucl Med Commun 1996; 17:851-856.
9. Iqbal SM, Khalil ME, Lone BA, Gorski R, Blum S, Heller EN. Simple techniques to reduce bowel activity in cardiac SPECT imaging. Nucl Med Commun 2004; 25:355-359.
10. Boz A, Karayalçin B. Which is better for inferior wall evaluation: a full or empty stomach. J Nucl Med 1996; 37:1916-1917.
11. Boz A, Yildiz A, Gungor F, Karayalçin B, Erkilic M. The volume effect of the stomach on intestinal activity on same-day exercise-rest Tc-99m tetrofosmin myocardial imaging. Clin Nucl Med 2001; 26:622-625.
12. Boz A, Gungor F, Karayalçin B, Yildiz A. The effects of solid food in prevention of intestinal activity in Tc-99m tetrofosmin myocardial perfusion scintigraphy. J Nucl Cardiol 2003; 10:161-167.
13. Russo A, Fraser R, Horowitz M. The effect of acute hyperglycaemia on small intestinal motility in normal subjects. Diabetologia 1996; 39:984-989.
14. Weinmann P, Moretti J.-L. Metoclopramide has no effect on abdominal activity of Sestamibi in myocardial SPET. Nucl Med Commun 1999; 20:623-625.
15. Pinkert J, Kutzner H, Lindner C, Lopez J, Kropp J, Franke WG. Reduction of artefacts related to intestinal activity in myocardial perfusion SPECT with Sestamibi. J Nucl Med 1997; 38(suppl):75p.
16. Grüning T, Jones IW, Nevin SM. Can administration of metoclopramide reduce artefacts related to abdominal activity in myocardial perfusion SPECT (MPS)? Autumn Meeting of the British Nuclear Medicine Society, Manchester, 2003, Abstract Booklet, p. 4.
17. Middleton GW, Williams JH. Significant gastric reflux of technetium-99m-MIBI in SPECT myocardial imaging. J Nucl Med 1994; 35:619-620.
18. Kabasakal L, Collier D, Shaker R, Hellman RS, Smart S, Ozker K, et al. Enterogastric bile reflux during technetium-99m-sestamibi cardiac imaging. J Nucl Med 1996; 37:1285-1288.
19. m radiopharmaceuticals in SPET myocardial perfusion imaging. Nucl Med Commun 1996; 17:114-118.
20. DePuey EG, Garcia EV (editors). Updated imaging guidelines for nuclear cardiology procedures, Part 1. J Nucl Cardiol 2001; 8:G1-G58.
21. Munch G, Neverve J, Matsunari I, Schröter G, Schwaiger M. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease. J Nucl Med 1997; 38:428-432.
22. Nuyts J, Dupont P, van den Maegdenbergh, Vleugels S, Suetens P, Mortelmans L. A study of the liver-heart artifact in emission tomography. J Nucl Med 1995; 36:133-139.
23. Buvat I, Benali H, Todd-Pokropek A, Di Paola R. Scatter correction in scintigraphy: the state of the art. Eur J Nucl Med 1994; 21:675-694.
24. Narayanan M, King MA, Pretorius PH, Dahlberg ST, Spencer F, Simon E, et al. Human-observer receiver-operating characteristic evaluation of attenuation, scatter, and resolution compensation strategies for 99mTc myocardial perfusion imaging. J Nucl Med 2003; 44:1725-1734.
25. Hendel RC, Berman DS, Cullom JS, Follansbee W, Heller GV, Kiat H, et al. Multicenter clinical trial to evaluate the efficacy of correction for photon attenuation and scatter in SPECT myocardial perfusion imaging. Circulation 1999; 99:2742-2749.
26. 99mTc-sestamibi myocardial perfusion imaging. J Nucl Med 2002; 43(suppl):197P.
27. Anagnostopoulos C, Harbinson M, Kelion A, Kundley K, Loong CY, Notghi A, et al. Procedure guidelines for radionuclide myocardial perfusion imaging (Adopted by the British Cardiac Society, the British Nuclear Cardiology Society, and the British Nuclear Medicine Society). Nucl Med Commun 2003; 24:1105-1119.
28. Harrington RA, Hamilton CW, Brodgen RN, Linkewich JA, Romankeiwicz JA, Heel RC. Metoclopramide: an updated review of its pharmacological properties and clinical use. Drugs 1983; 25:451-494.
29. Spellman SJ, Shaffer EA, Rosenthall L. Gallbladder emptying in response to cholecystokinin. A cholescintigraphic study. Gastroenterology 1979; 77:115-120.
30. Jain D, Wackers FJ, Mattera J, McMahon M, Sinusas AJ, Zaret BL. Biokinetics of technetium-99m-tetrofosmin myocardial perfusion imaging agent: implications for a one-day imaging protocol. J Nucl Med 1993; 34:1254-1259.
31. Savi A, Gerundini P, Zoli P, Maffioli L, Compierchio A, Columbo F, et al. Biodistribution of Tc-99m methoxy-isobutyl-isonitrile (MIBI) in humans. Eur J Nucl Med 1989; 15:597-600.
32. Flamen P, Bossuyt A, Franken PR. Technetium-99m-tetrofosmin in dipyridamole-stress myocardial SPECT imaging: intra-individual comparison with technetium-99m-sestamibi. J Nucl Med 1995; 36:2009-2015.
33. Kapur A, Latus KA, Davies G, Dhawan RT, Eastick S, Jarritt PH, et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur J Nucl Med 2002; 29:1608-1616.
34. Primeau M, Taillefer R, Essiambre R, Lambert R, Honos G. Technetium 99m SESTAMIBI myocardial perfusion imaging: comparison between treadmill, dipyridamole and trans-oesophageal atrial pacing “stress” tests in normal subjects. Eur J Nucl Med 1991; 18:247-251.